ResearcherSpanish Biomedical Research Centre in Physiopathology of Obesity and NutritionActive in the last 2 years
Justo Pastor Castano
Matched on ORCID iD 0000-0002-3145-7287; OpenAlex author ID A5059027410. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 27
2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers
Papers 7
- Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. Last author DOI 10.1002/1878-0261.13658↗
- Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems. Co-author DOI 10.1016/j.semcancer.2024.09.002↗
- The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41417-024-00814-3↗
- Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. Last author DOI 10.1186/s13046-023-02858-z↗
- Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14235993↗
- Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Last author DOI 10.1186/s13046-021-02153-9↗
- Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmed.2021.720128↗
Closest collaborators
The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Emilia Alors‐Pérez · 6 shared papers, 2021–2024 · strength 0.84
- Paper Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. DOI 10.1186/s13046-023-02858-z↗
- Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
- Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
- Ricardo Blázquez‐Encinas · 4 shared papers, 2021–2024 · strength 0.61
- Paper Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. DOI 10.1186/s13046-023-02858-z↗
- Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
- Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
- Andrea Mafficini · 3 shared papers, 2021–2024 · strength 0.43
- Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
- Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
- Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
- Rita Teresa Lawlor · 3 shared papers, 2021–2024 · strength 0.43
- Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
- Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
- Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
- Aldo Scarpa · 3 shared papers, 2021–2024 · strength 0.43
- Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
- Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
- Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
- Iranzu González‐Borja · 3 shared papers, 2021–2024 · strength 0.39
- Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993↗
- Paper Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fmed.2021.720128↗
- Antonio Viúdez · 3 shared papers, 2021–2024 · strength 0.39
- Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
- Paper Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. DOI 10.3390/cancers14235993↗
- Paper Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fmed.2021.720128↗
- Bruno Sáinz · 2 shared papers, 2021–2023 · strength 0.27
- Paper Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. DOI 10.1186/s13046-023-02858-z↗
- Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
- Claudio Luchini · 2 shared papers, 2021–2024 · strength 0.26
- Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
- Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
- Joaquín Fernández‐Irigoyen · 2 shared papers, 2021–2022 · strength 0.23
- Ruth Vera · 2 shared papers, 2021–2022 · strength 0.23
- Benoît Immordino · 1 shared paper, 2024 · strength 0.19
- Macarena Perán · 1 shared paper, 2024 · strength 0.19
- Manoj Amrutkar · 1 shared paper, 2024 · strength 0.19
- Naomi Walsh · 1 shared paper, 2024 · strength 0.19
- Cristina P. R. Xavier · 1 shared paper, 2024 · strength 0.19
- Rita Rebelo · 1 shared paper, 2024 · strength 0.19
- Alessandro Gregori · 1 shared paper, 2024 · strength 0.19
- Belén Toledo · 1 shared paper, 2024 · strength 0.19
- Giulia Lencioni · 1 shared paper, 2024 · strength 0.19
- Elisa Giovannetti · 1 shared paper, 2024 · strength 0.19
- Corinne Bousquet · 1 shared paper, 2024 · strength 0.18
- Ismael Ghanem · 1 shared paper, 2022 · strength 0.13
- Roberto Pazo-Cid · 1 shared paper, 2022 · strength 0.13
- Javier Gallego-Plazas · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.